Drugnews

Updated

Atopic dermatitis: Asian pipelines and global competitors

As of 2026-11-14, Asian participation in atopic dermatitis includes Simcere’s rademikibart, Chugai-originated nemolizumab and SinoMab’s SM17, targeting IL-4Rα, IL-31RA and the IL-25 receptor pathway, respectively. Approved global comparators include dupilumab and lebrikizumab. Kyowa Kirin announced discontinuation of all ongoing rocatinlimab trials on 2026-03-03; it is listed separately as a discontinued program.

Skin barrier and immune signaling

Selected systemic biologics; oral JAK inhibitors and topical medicines are not exhaustively covered. Originator and regional rights are distinguished.

Asian companies

AssetCompanyMechanism / routeStageIndicationTrial IDDeal / rightsLatest verified recordSources
rademikibart
Simcere / Connect
Anti-IL-4Rα antibody
SC
Phase 3 completed; NDA withdrawn with resubmission planned
Moderate-to-severe atopic dermatitis
—
Simcere holds China development, manufacturing and commercialization rights; amounts not verified
The 04-22 release says the NDA was withdrawn, with resubmission planned that month; primary confirmation of reacceptance was not identified.
nemolizumab / NEMLUVIO
Chugai; Galderma and regional partners
Anti-IL-31RA antibody
SC
Approved; indications vary by jurisdiction
Atopic dermatitis / associated pruritus, per local labels
—
No verified deal terms identified
Chugai announced a drug-discovery award for nemolizumab; this is a research award, not a new indication approval.
SM17
SinoMab (Hong Kong)
Anti-IL-25 receptor (IL17RB) antibody
SC
Phase 2; recruiting per registry
Moderate-to-severe atopic dermatitis
No verified deal terms identified
Reported first dosing in China Phase 2 on 03-31; approximately 210 participants are planned, not confirmed enrolled.

Global comparators

AssetCompanyMechanism / routeStageIndicationLatest verified recordSources
dupilumab / Dupixent
Sanofi / Regeneron
Anti-IL-4Rα antibody
SC
Approved
Atopic dermatitis; ages depend on jurisdiction
Signed a Canadian pCPA letter of intent including pediatric AD; this does not establish reimbursement in every province.
lebrikizumab / EBGLYSS
Eli Lilly
Anti-IL-13 antibody
SC
Approved
Moderate-to-severe atopic dermatitis
Q3 results highlighted Phase 3 hand-and-foot AD data; this is not a new approval announcement.

Discontinued program

AssetCompanyMechanism / routeStageIndicationLatest verified recordSources
rocatinlimab
Kyowa Kirin
Anti-OX40 antibody
SC
Discontinued; historical Phase 3 program
Moderate-to-severe AD and other indications
Announced discontinuation of all ongoing trials following emerging safety concerns.

Events in the last 90 days

2026-08-17 – 2026-11-14

Sources and downloads

  1. Simcere HKEX regulatory update — 2026-04-22
  2. Simcere RADIANT-AD — 2026-03-30
  3. Chugai nemolizumab award — 2026-09-07
  4. SinoMab HKEX first patient dosed — 2026-04-01
  5. SM17 Phase 2 registry — 2026-04-06
  6. Sanofi Canada pCPA LOI — 2026-10-15
  7. Lilly Q3 2026 results — 2026-10-29
  8. Kyowa Kirin discontinuation — 2026-03-03

Information cutoff 2026-11-14